Clinical Case Discussion Forum
To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion using this forum.
Dasatinib induced severe thrombocytopenia
I would appreciate your expert opinion regarding a 24-year-old patient with high-risk Sokal CML in the chronic phase. The patient was diagnosed in June 2026, with WBC 413, Hb 6.7 g/dL, platelets 607–870, massive splenomegaly (7 fingerbreadths below the costal margin), and BCR-ABL1 p210 of 55%. Dasatinib was initiated on 16/06/2026.
On 27/07/2026, the patient developed grade 4 pancytopenia (platelets 11, ANC 0.3), which resolved within 3 weeks after discontinuation. Dasatinib was restarted at 50 mg on 16/08/2026 (platelets 545, Hb 10.6, WBC 5.3) and increased to 100 mg on 23/08/2026. On 17/09/2026, platelets dropped to 84, so the dose was reduced to 50 mg. Treatment was stopped on 27/09/2026 when platelets further declined to 38.
Additional available information:
- Bone marrow histology: The initial bone marrow biopsy showed no fibrosis. A repeat bone marrow biopsy was performed during the episode of severe thrombocytopenia and revealed a hypocellular marrow with no significant fibrosis.
- Cytogenetics: Conventional cytogenetic analysis was not performed at diagnosis due to limited local resources.
- BCR::ABL1 transcript: The available report indicates BCR::ABL1 positivity 51% however, the exact transcript subtype was not specified.
The patient remains off treatment, with persistent severe thrombocytopenia. Latest CBC Hb 12.5 g/dL, WBC 4.6 /L, ANC 2.8 and platelets 17. There is no palpable splenomegaly currently. Smear showed severe thrombocytopenia bone marrow biopsy showed marked hypocellularity however, the specimen was small, and no megakaryocytes were identified.
I would appreciate your opinion regarding this isolate severe thrombocytopenia and the safest subsequent CML treatment strategy.
This is a difficult case and the work up for the thrombocytopenia seems to have been appropriate. So the question that needs answering is what is the cause of the thrombocytopenia as this can dictate the management. Is it due to the disease, the therapy, an underlying bone marrow problem or something totally unrelated.
Important possibilities such as marrow fibrosis or ITP appear to have been eliminated by the work up - no fibrosis and no megas. The CML appears to respond to the DAS with count suppression. It has only been about a month since the DAS was held, and Hgb and neuts have recovered but plt recovery may just be delayed. It is not certain whether the recovering counts are normal hemopoiesis or CML hemopoiesis. The fact that DAS suppresses suggests to me that it is malignant hemopoiesis as it is still TKI sensitive. I expect that counts will recover over the next few weeks. What then?
I would doubt that this is a specific DAS issue, but on count recovery one more attempt with a different TKI can be made, but I expect the same issue, namely that normal hemopoiesis is still suppressed and only malignant but normal looking count recovery is happening. Normal hemopoiesis is dormant or suppressed for some reason. This process could be repeatedly attempted, but the risk of disease progression remains. Playing roulette with different TKIs will likely not solve the problem. The use of growth factor support +/- transfusion support would be a very aggressive management addition. Other investigations such as cytogenetics may shed a little more light on the problem but will not solve it.
If I were managing this case in a very young man, I would now or after one more unsuccessful attempt with a different TKI, proceed to an allograft, which could be matched sibling or haplo as I expect in Saudi Arabia, the availability of family is a given. There is only one mistake here to my mind and that is to wait. HSCT side effects are for the most part manageable and the cure rate is very high.
Isolated recurrent thrombocytopenia due to Dasatinib usage in CP-CML is usually managed by drug interruption and dose reduction. However, in this case I will advise serial monitoring of CBC. Give supportive eltrombopag if signs of bleeding occur and subsequently replace Dasatinib with other TKIs such as Nilotinib, Imatinib etc if thrombocytopenia persists.
I would add that at presentation the Hb level was 67 g/l and now it has reached normal value of 127 g/l. This fact suggests that hematopoiesis at this stage can be normal and CML-clone derived.
Thus, would it be my patient, I would try TPOR-agonist (avatrombopag or eltrombopag) and after platelets' rise above 100 000/mm3, restart dasatinib at 50 mg/day.